GlcNAc Pathway-based Cell Surface Metabolic Glycoengineering Service

Significance of GlcNAc Pathway-based Cell Surface Metabolic Glycoengineering (MGE) for Bioprocess Research

GlcNAc pathway refers to the pathway in which N-acetylglucosamine is involved in metabolism in organisms. GlcNAc pathway involves several biological processes and metabolic pathways, including glucose metabolism, aminoglycol metabolism, chitosan synthesis, and glycoprotein modification. GlcNAc pathway-based cell surface MGE utilizes the biosynthetic pathway for the modification and processing of glycan molecules on the cell surface. Utilizing this technique, the regulation of biomolecular complexity and diversity can be realized, which has a wide range of application prospects. By modifying the sugar moiety modifications on the cell surface, the interactions between cells and other cells or molecules can be altered, thereby affecting physiological processes such as cell signaling, adhesion, recognition, and immune response. This is of great significance for the study of cell function, in-depth understanding of disease mechanisms, as well as for drug development and screening.

Fig.1 Schematic representation of UDP-N-acetylglucosamine synthesis. (Rani & Khan, 2018) Fig.1 Schematic representation of UDP-N-acetylglucosamine synthesis. (Rani & Khan, 2018)

GlcNAc Pathway-based Cell Surface MGE Service at CD BioGlyco

CD BioGlyco is an A-level biotech company focusing on research and applications related to glycan modification. We have developed our own Glycoengineering Platform to provide the most advanced Metabolic Pathway-based Cell Surface Glycoengineering Service. In particular, the GlcNAc pathway-based Cell Surface MGE Service is designed to help our clients achieve precise modification for a variety of applications. The details of our services are as follows:

  • Substrate preparation
    We obtain substrates required for cell surface modification, such as glycosaminoglycans (e.g., acetylheparin, heparin) or O-glycans (e.g., glucose, galactose, mannose), by biosynthesis or chemical synthesis.
  • Process of modification
    First, we modulate the intracellular GlcNAc metabolic pathway by regulating the expression or activity of enzymes involved in the metabolic pathway to UDP-GlcNAc or UDP-GalNAc. For example, by transfecting exogenous genes to increase the expression of key enzymes. The use of glycosyltransferases enables the addition of specific sugar groups to the substrate, modifying the substrate into the target sugar molecule. Therefore, we utilize members of the glycosyltransferase family to modify the regulated GlcNAc metabolites. Finally, we optimize the glycosyltransferase-catalyzed reaction to improve efficiency and product purity.
  • Process of analysis
    We use techniques such as chromatography and flow cytometry to identify and quantify the extent and type of the modifications.

Fig.2 Process of GlcNAc pathway-based cell surface MGE. (CD BioGlyco)Fig.2 Process of GlcNAc pathway-based cell surface MGE. (CD BioGlyco)

Applications

  • Through cell surface MGE, the type and abundance of cellular glycan modifications can be altered to improve drug targeting.
  • Altering the glycan modification of the cell surface affects the interaction of the cell with the material surface, thereby enhancing the biocompatibility of the biomaterial.
  • Cell surface MGE enables targeted modification of cell surface glycoproteins to study its biological functions.

Advantages of Us

  • GlcNAc pathway-based cell surface MGE is flexible to meet your research needs and applications in different fields.
  • We have a highly efficient glycoengineering expression system, which is capable of rapid and accurate expression and modification of glycan modifications.
  • Through an in-depth understanding of our client's research objectives and application needs, we combine advanced glycoengineering technologies to provide customized experimental solutions for our clients.

CD BioGlyco provides customized GlcNAc pathway-based cell surface MGE services according to the different needs of clients to help them achieve a wider range of research objectives and applications. Our service covers a wide range of technologies and methods from substrate supply and metabolic pathway regulation to glycosyltransferase catalysis. If you need related services, please feel free to contact us for more information.

Reference

  1. Rani, C.; Khan, I.A. UDP-GlcNAc pathway: Potential target for inhibitor discovery against M. tuberculosis. European Journal of Pharmaceutical Sciences. 2016, 83: 62-70.
This service is for Research Use Only, not intended for any clinical use.

Christmas 2024

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0